Amanda M. Goceljak

While attending Columbia Law School, she served as the editor in chief of the Columbia Journal of Asian Law. Prior to joining Morgan Lewis, she was an associate in the corporate practice of a prominent international law firm.

• Gilead in its collaboration agreement with Scholar Rock Holding for the development and commercialization of Scholar Rock’s novel therapies for fibrotic diseases targeting latent TGF-beta1
• Incyte in its agreement with Foundation Medicine for the development, regulatory support and commercialization of companion diagnostics, with an initial focus on CDx development for Incyte’s selective FGFR1/2/3 inhibitor in patients with cholangiocarcinoma
• Regeneron in its agreement with bluebird bio to develop and commercialize new cell therapies for cancer. As part of the transaction, Regeneron made a $100 million investment in bluebird bio common stock
• Celgene in its licensing agreement with Amunix relating to Amunix's XTEN and ProTIA technology to augment the discovery and development of therapeutic products
• Celgene in its drug-discovery collaboration with Cancer Research Technology (CRT), to discover, develop and commercialize new anti-cancer treatments centered on mRNA translation 
• Shire in its agreement with Novimmune granting Shire exclusive worldwide rights to develop, manufacture and commercialize novel bispecific antibodies for the treatment of hemophilia A
• AstraZeneca in the co-development agreement between its subsidiary, Pearl Therapeutics, and Avillion for the global advancement of Pearl Therapeutics’ PT027, a treatment for asthma
• Merck KGaA in its clinical co-development agreement with Avillion to develop through Phase III Merck’s bi-specific anti IL-17 A/F Nanobody® for plaque psoriasis
• Regeneron in its licensing and collaboration agreement with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development, with Intellia receiving a $75 million upfront payment and potential milestone and royalties
• Teva in connection with its $40.5 billion acquisition of Allergan’s worldwide generic pharmaceutical business
• GSK in the sale of its rights to Prolia® (denosumab), XGEVA (denosumab) and Vectibix (panitumumab) to Amgen
• Incyte in its license and collaboration agreement with Jiangsu Hengrui Medicine for the development and commercialization of SHR-1210, an investigational anti-PD-1 monoclonal antibody, worldwide except mainland China, Hong Kong, Macau, and Taiwan
• Merck in the sale of its ophthalmics business
• GSK in the formation of the Altius Institute for Biomedical Sciences, an independent, non-profit research institute, in Seattle, Washington, to be led by Dr. John A. Stamatoyannopoulos 
• Merck in its $14.2 billion agreement to sell its consumer care business to Bayer

Results may vary depending on your particular facts and legal circumstances.